The Registry Study of Takayasu Arteritis in East China

Launched by SHANGHAI ZHONGSHAN HOSPITAL · Mar 25, 2019

Keywords

ClinConnect Summary

This clinical trial, called "The Registry Study of Takayasu Arteritis in East China," is focused on understanding a rare condition known as Takayasu arteritis (TA), which mainly affects women in Asia, including China. The study aims to gather a large group of participants with this condition to improve how we manage and treat TA, especially for women who plan to become pregnant. Researchers will use blood and tissue samples from participants to explore better treatment options and improve patient outcomes.

To be eligible for the trial, participants should be under 40 years old and have certain symptoms like pain in their limbs, a weak pulse in their arms, or specific blood pressure differences between their arms. They must also meet at least three of the study's criteria. It's important to know that people with other autoimmune diseases or serious health problems may not qualify for this trial. Participants can expect to contribute to a better understanding of this condition and possibly help develop new treatment strategies. The study is currently recruiting participants of all genders, and anyone interested should speak with their doctor for more information.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • onset at age ≤40 years;
• • claudication of an extremity;
• • decreased brachial artery pulse;
• • \>10 mm Hg difference in systolic blood pressure between arms;
• • a bruit over the subclavian arteries or the aorta;
• • angiographic evidence of narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the proximal upper or lower extremities.
• • Patients should meet at least 3 of the above 6 articles.
• • Sign the informed consent
• • Exclusion Criteria
• • autoimmune diseases, such as ANCA-associated vasculitis, systemic lupus erythematosus, Behcet's disease, rheumatoid arthritis, ankylosing spondylitis, etc.;
• • complicated medical abnormal conditions, un-related with TA but engendering the unpredictable risks, such as severe, progressive, or uncontrollable kidney, liver, blood, gastrointestinal, pulmonary, heart, neuron or others
• • malignant tumors;
• • serious acute or chronic infections;
• • high risk of tuberculosis infection such as clinical, radiological or laboratory evidence of active or occult tuberculosis, or the history of active tuberculosis;
• • Having received or plan to receive plasma exchange or lymphocyte replacement or immunoabsorption therapy within 1 year.
• • Preparing to receive an attenuated vaccine during the trial;
• • Having received or plan to receive an organ transplant;
• • Exit criteria
• • participants require to withdraw during the study;
• • participants who believe that they need to withdraw due to clinical adverse events;
• • Participants can not or does not comply with the requirements of the research protocol;